|
|
Article: Rash portends better outcome of cancer drug.(ACROSS SPECIALTIES)
- Article from:
- Skin & Allergy News
- Article date:
- March 1, 2009
- Author:
CopyrightCOPYRIGHT 2009 International Medical News Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN FRANCISCO -- Patients receiving erlotinib-based therapy for metastatic pancreatic cancer are less likely to experience progression and to die if they develop a rash, Dr. Eric Van Cutsem reported at the annual gastrointestinal cancers symposium sponsored by the American Society of Clinical Oncology.
The finding comes from a second look at data generated by the placebo-controlled phase III AViTA trial.
AViTA reported improved progression-free survival, but not overall survival, with the addition of bevacizumab (Avastin) to combined erlotinib (Tarceva) and gemcitabine (Gemzar) therapy in patients having previously untreated metastatic pancreatic cancer ...